Kidney Disease Market Size, Share, and Trends Report by 2031

The kidney disease market size was estimated to be US$ 91.16 billion in 2021 and US$ XX billion in 2023 and is expected to reach US$ 176.51 billion by 2031; it is estimated to record a CAGR of 8.0% in 2023–2031. 

Nascent consumer-driven and safety-observant products have been motivated by the rising prevalence of kidney diseases, and an increasing number of geriatric patients are willing to stay at home for treatment. Such advanced therapeutic alternatives are likely to remain key kidney disease market trends. 

Kidney Disease Market Analysis

Chronic kidney disease (CKD) is a common and life-threatening condition that affects 1 in 10 people worldwide. High blood pressure and diabetes account for two-thirds of all cases of CKD. Moreover, in 2020, as per the study published by the National Kidney Foundation, roughly 35% of the diabetic population above 20 years age would develop chronic kidney disease over the period.  Furthermore, the World Health Organization outlined various strategies to maintain policy-makers policies, including vital medicine list concept and the universal health coverage (UHC) approach. Moreover, with the increasing cost of living, reimbursed for utilities is essential on home dialysis treatment. European countries have developed reimbursement systems that intend to offer various crucial medicines at no cost or a reduced cost. For instance, in February 2024, the Scottish government introduced the first-ever national guidelines for reimbursement for home dialysis people in Scotland following campaigning from Kidney Care UK. Also, in Wales, reimbursement is offered for all forms of home dialysis. These factors are expected to boost market growth during the forecast period.

Kidney Disease Market Overview

In CKD, kidneys are damaged and cannot filter blood, which causes excess fluid and waste from blood in body which causing other health problems, such as heart disease and stroke. The Centers for Disease Control and Prevention (CDC) stated that more than 1 in 7 US adults, about 35.5 million people or 14%, have CKD. 9 in 10 adults are unaware of having CKD and 1 in 3 adults with severe CKD are not aware of having CKD.  Another major driver of the market is the increasing geriatric population as aging is the risk factor for growing incidences of renal diseases. For instance, according to a study published by the Population Reference Bureau (PRB) in 2024, Americans above 65 and older is projected to increase from 58 million in 2022 to 82 million by 2050, an increase by 47% and of total population share will increase from 17% to 23%. Continuous support from the U.S. government will provide lucrative opportunities in the country. For instance, in February 2024, Simple HealthKit launched a new kidney care program to support health plans, this program provides early detection to help patients achieve better outcomes and drastically reduce the cost of care. Simple HealthKit partnered with commercial and government health plans on its existing offerings and works with them to design custom testing programs that can deployed to connect with hard-to-reach members.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

Kidney Disease Market: Strategic Insights

Kidney Disease Market

• 
  CAGR (2023 - 2031)

  8.0%
• Market Size 2021
  US$ 91.16 Billion
• Market Size 2031
  US$ 176.51 Billion

Market Dynamics

GROWTH DRIVERS

• Favorable Reimbursement Policy for Kidney Disease Treatments
• High Prevalence of Chronic Diseases Leading to Kidney Diseases

FUTURE TRENDS

• Rise in Preference for Advanced Hemodialysis Therapies

OPPORTUNITIES

• Increase in Preference for Robotic Surgeries for Kidney Diseases

Key Players

• Abbott Laboratories
• Amgen Inc
• F Hoffmann La Roche Ltd
• GlaxoSmithKline PLC
• Pfizer Inc
• Siemens Healthineers
• Sysmex Corporation
• Teva Pharmaceutical Industries Ltd
• Siemens Healthineers AG
• AbbVie Inc

Regional Overview

• North America
• Europe
• Asia-Pacific
• South and Central America
• Middle East and Africa

Market Segmentation

Product Type

• Diagnosis
• Treatment

End User

• Hospital
• Diagnostic Laboratories

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Kidney Disease Market Drivers and Opportunities

High Prevalence of Chronic Diseases Leading to Kidney Diseases to Favor Market

Chronic kidney disease impairs kidney function and cause kidney damage. Diseases and conditions that cause chronic kidney disease include diabetes and High blood pressure. As per the report published in the National Library of Medicine (NLM), about 80% of the global diabetes burden comes from low-and-middle-income countries, and 60% of cases are in Asia, i.e., 6 of 10 countries with the highest prevalence of diabetes are in Asia. As per the World Economic Forum, China is one of the highest rates of diabetes in the world and is continuing to worsen. In China, in 2021, an estimated 141 million diabetics were in the country and its prevalence in adults aged 20-79 years is projected to increase from 8.2% to 9.7% during 2020-2030.

Increase in Preference for Robotic Surgeries for Kidney Diseases– An Opportunity

According to the National Kidney Foundation Inc., kidney disease has a higher risk for kidney cancer, and it is the second leading cause of death with chronic kidney disease (CKD) patients. For a precise excision of the tumor, the Robotic partial nephrectomy approach is used to maintain healthy and functional parts of the kidney intact. Also, F.A.S.T. robotic partial nephrectomy is an enhanced approach to surgically remove a kidney tumor and reconstruct the kidney to prevent functional damage. Adoptions of robotics in surgeries has increased significantly across various North American, European, and Asian countries.

Kidney Disease Market Report Segmentation Analysis

Key segments that contributed to the derivation of the kidney disease market analysis are product type and end user.

• Based on product type, the kidney disease market is divided into diagnosis and treatment. The diagnosis segment is sub-segmented into blood tests, urine tests, imaging tests, and others. The treatment segment is further sub-segmented into drug class, dialysis, and others. The diagnosis segment held a larger market share in 2023.
• By end user, the market is segmented into diagnostic laboratories, hospitals, and others. The hospitals segment held the largest share of the market in 2023.

Kidney Disease Market Share Analysis by Geography

The geographic scope of the kidney disease market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South America/South & Central America.

North America has dominated the kidney disease market. In the United States, about 15% of adults have chronic kidney disease. Some 37 million people in the U.S. are living with chronic kidney disease. North America held the largest share in 2022. Due to rising incidences of CKD in the region and presence of global market players are factors contributing to the dominance of the North America kidney disease market. Asia Pacific is anticipated to grow with the highest CAGR in the coming years.  

Kidney Disease Market News and Recent Developments

The Kidney Disease Market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. The following is a list of developments in the market for kidney disease:

• Boehringer Ingelheim and Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) approved Jardiance (empagliflozin) 10 mg tablets to reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, cardiovascular death and hospitalization in adults with chronic kidney disease (CKD) at risk of progression. (Source: Boehringer Ingelheim and Eli Lilly and Company/Company Website, September 2023)
• The U.S. Food and Drug Administration approved Farxiga (dapagliflozin) oral tablets to reduce the risk of kidney function decline, kidney failure, cardiovascular death and hospitalization for heart failure in adults with chronic kidney disease who are at risk of disease progression. (Source: U.S. Food & Drug Administration, Press Release, April 2021)

Kidney Disease Market Report Scope

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Kidney Disease Market Report Coverage and Deliverables

The “Kidney Disease Market Size and Forecast (2022–2030)” report provides a detailed analysis of the market covering below areas:

• Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
• Market dynamics such as drivers, restraints, and key opportunities
• Key future trends
• Detailed PEST/Porter’s Five Forces and SWOT analysis
• Global and regional market analysis covering key market trends, major players, regulations, and recent market developments
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments
• Detailed company profiles